Nanobiotix

Historical price data

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

Proprietary nanoparticle platforms, including the Nanoradioenhancer Platform (hafnium oxide nanoparticles that amplify radiotherapy dose) and the Curadigm Nanoprimer Platform, focused on physics-based therapeutic interventions.